AI assistant
Hamilton Lane INC — Director's Dealing 2017
Mar 8, 2017
30753_dirs_2017-03-08_f20fe7a4-baec-4b30-ab74-f002b07c5721.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Hamilton Lane INC (HLNE)
CIK: 0001433642
Period of Report: 2017-03-06
Reporting Person: Delgado-Moreira Juan (Managing Director, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-03-06 | Class A Common Stock | J | 1550965 | — | Acquired | 1550965 | Direct |
| 2017-03-06 | Class A Common Stock | P | 2800 | $16 | Acquired | 1553765 | Direct |
| 2017-03-06 | Restricted Class A Common Stock | J | 77868 | — | Acquired | 1628833 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-03-06 | Employee Stock Option (right to buy) | $1.34 | J | 233495 | Acquired | 2017-06-01 | Class A Common Stock (233495.0) | Direct |
Footnotes
F1: In the reorganization (the "Reorganization") of Hamilton Lane Advisors, L.L.C. ("HLA") in connection with the Issuer's initial public offering (the "IPO"), the reporting person exchanged membership interests of HLA owned prior to the IPO for Class A Common Stock of the Issuer.
F2: Purchase of shares in Issuer's directed share program in connection with its initial public offering.
F3: Represents the number of shares issued to the reporting person pursuant to an award of restricted stock under the Issuer's 2017 Equity Incentive Plan. The award was issued in substitution for existing awards of restricted interests in HLA that were issued annually in the years prior to the IPO, and the new award vests according to the same vesting schedule as the replaced awards: in four equal annual installments each March. Accordingly, one tranche will vest in 2017, one in 2018, one in 2019 and one in 2020.
F4: These options were granted under the Issuer's 2017 Equity Incentive Plan in substitution for outstanding options to purchase non-voting interests of HLA that were issued in 2007, prior to the IPO. The options being replaced were fully vested, and so the substitute award is fully vested.